Monash-Led Graphene Sensor Backed for Early Cancer Detection

Industry Insights from Next Move Strategy Consulting

In a significant advancement for cancer diagnostics, Monash University and Monash Health have received a $100,000 grant from the Love Your Sister Foundation to support development of a graphene oxide (GO)-based biosensor for early cancer detection. This interdisciplinary effort seeks to harness the unique properties of graphene oxide to identify circulating tumour DNA (ctDNA) in blood and urine, potentially enabling earlier diagnosis and personalised monitoring of cancer progression.

Pioneering a New Approach to Cancer Biomarker Detection

Detecting ctDNA — the fragments of tumour DNA shed into bodily fluids — with high sensitivity could revolutionise how clinicians identify and track cancer. The GO-ctDNA biosensor, led by an expert team of engineers, oncologists and nanotechnology specialists, is designed to bind specific cancer-linked mutations to the surface of graphene oxide and signal their presence through fluorescence. Its development leverages advanced nanofabrication and synchrotron techniques to enhance both sensitivity and practicality for medical settings.

“This project represents a perfect convergence of engineering innovation and clinical need,” said Dr Gwo Yaw Ho, Head of the Cancer Immunology Laboratory at Monash Health and Monash University, underscoring the potential of the biosensor to detect cancer mutations even before symptoms appear.

The eventual goal is to create a portable, cost-effective diagnostic tool that extends beyond specialised laboratories, making early cancer testing feasible in broader clinical environments, including outpatient and regional care settings.

Interdisciplinary Collaboration Driving Innovation

The GO-ctDNA project unites expertise in oncology, engineering, structural biology and nanofabrication from across Monash Health, Monash University and national research facilities. Key contributors include Professor Raman Singh (Mechanical and Aerospace Engineering), Professor Nicolas Voelcker (Melbourne Centre for Nanofabrication), Dr Santosh Panjikar (Australian Synchrotron, ANSTO), Dr Yi Tian Ting (Structural Biology) and Dr Jenny Dyson (Mechanical and Aerospace Engineering).

Next Move Strategy Consulting: Potential Industry Impact

According to Next Move Strategy Consulting, the development of graphene-based biosensors like the GO-ctDNA could significantly shift investment focus within biomedical diagnostics toward highly sensitive, non-invasive technologies. Enhanced early detection tools are likely to accelerate innovation in precision medicine, drive competition among diagnostic manufacturers, and support broader adoption of point-of-care testing solutions — ultimately improving patient outcomes and lowering long-term healthcare costs.

By advancing graphene sensor technology from research to real-world application, this initiative exemplifies how targeted funding and interdisciplinary collaboration can accelerate transformational changes in cancer care.

Source: Monash University

Prepared by: Next Move Strategy Consulting